On April 19, 2021, Amgen announced its launch of Biomarker AssistTM—a program to help patients with metastatic non-small cell lung cancer (NSCLC) gain access to biomarker testing. Through this new program, eligible patients may save on costs related to biomarker testing.
Learn more about Biomarker AssistTM on its website.
Read the Amgen announcement.
Posted 4/19/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
